Could a cancer drug change how other medicines work? a trial investigates
NCT ID NCT07744802
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether vimseltinib, an investigational drug, affects how the body processes a common blood thinner called dabigatran. Healthy male volunteers will take both drugs in a fixed order, and researchers will measure dabigatran levels in the blood to see if vimseltinib changes its absorption or breakdown. The goal is to understand potential drug interactions, which could help guide safe dosing when vimseltinib is used alongside other medications. The study lasts about three weeks and also monitors for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vimseltinib (an investigational drug) and dabigatran (a blood thinner used as a test probe)
- What this could lead to
- If vimseltinib changes how the body processes other drugs, doctors may need to adjust doses when combining it with certain medications, improving safety for future patients.
- What could go wrong
- This is an early-stage study in a small group of healthy men, so results may not apply to patients or to other drugs. There is also a risk of unexpected side effects from the drug combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.